DEALS: Teva buys CoGenesys for $400M

DEALS

WHO

WITH

WHAT

SCOOP

Pfizer

Washington University

$25M

Washington University and Pfizer researchers will identify, design and execute projects focused on immuno-inflammatory disorders such as arthritis, asthma and diabetes.

Forest Laboratories

Novexel's

$109.6 million

Forest gains development rights to Novexel's intravenous beta lactamase inhibitor, NXL 104, in combination with Forest's ceftaroline.

Teva

CoGenesys

$400 million

Teva says the buyout will give it a better position to compete in the fledgling biogeneric field.